Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Companion Diagnostic Market Analysis

ID: MRFR/MED/2231-CR
168 Pages
Satyendra Maurya
Last Updated: April 09, 2026

Companion Diagnostics Market Research Report Information by Test Type (HER2 Testing, PD-1 Testing, EGFR Mutation Testing, ALK Rearrangement Testing, and Others), By Product & Services (assays, reagents & kits, instruments/systems, and software & services), By Technology (polymerase chain reaction (PCR), next-generation sequencing (NGS), immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), and others),By Indication (cancer, neurological disorders, cardiovascular disorders, and infectious diseases), By End User (Biopharmaceutical and Biotechnology Companies, CROs and CDMOs, and Others) By Region (North America, Europe, Asia-Pacific) - Forecast to 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Companion Diagnostic Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Methodology Download PDF

Market Analysis

In-depth Analysis of Companion Diagnostic Market Industry Landscape

In the healthcare industry, companion diagnostics is constantly evolving. The market in question is strongly related to personalized medicine, which co-develops diagnostic tests and focused treatment approaches to improve patient outcomes. Technology, targeted medicines, and individualized patient care affect the companion diagnostics industry. Technological innovation drives companion diagnostics market dynamics. Molecular biology, genomics, and proteomics have made diagnostic tests more accurate and advanced. Genetic testing and other companion diagnostics can identify people who will benefit from a medication. This allows doctors to tailor treatments to individual patients. The companion diagnostics market has grown and become complex due to targeted medicines. Pharmaceutical firms are developing increasingly focused and tailored therapies to identify acceptable patient groups, increasing demand for companion diagnostics. These diagnostics stratify patients by molecular or genetic profiles to ensure the right medicine is given at the right time. Market dynamics are also affected by regulations. Regulatory authorities oversee companion diagnostic approval and marketing to assure safety and effectiveness. Regulatory sanction emphasizes the need of rigorous validation and testing, enhancing healthcare practitioner confidence and encouraging widespread deployment. Increased awareness of customized medicine and focused medicines affect the companion diagnostics sector. Patients and doctors are increasingly aware of the value of individualized treatments that take into account individual characteristics. Companion diagnostics should be part of tailored healthcare as this becomes more apparent. Academic institutions, pharmaceutical businesses, and diagnostic companies use collaboration and partnerships to affect market dynamics. In companion diagnostics, strategic collaborations are common to create new medicinal medicines and diagnostic tests. These collaborations increase pharmaceutical development and provide a more coherent customized medicine approach. Additionally, economic factors and reimbursement rules might affect the companion diagnostics business. The financial sustainability of companion diagnostics depends on payment procedures, healthcare budget allocations, and cost-effectiveness studies. In order to optimize resources, healthcare systems prioritize companion diagnostics' cost-effectiveness and clinical usefulness, which shapes market dynamics. Global healthcare trends including the aging population and chronic illness prevalence boost the companion diagnostics industry. Due to the need for more effective and tailored medicines, companion diagnostics are becoming essential for cancer, cardiovascular, and neurological disease treatment choices. COVID-19 brought out the need for personalized therapy and quick diagnosis, affecting companion diagnostics. Companion diagnostics are crucial to addressing pressing healthcare challenges since the global health crisis has accelerated diagnostic technology development and adoption.

Author
Author Profile
Satyendra Maurya
Research Analyst

An accomplished research analyst with high proficiency in market forecasting, data visualization, competitive benchmarking, and others. He holds a pronounced track record in research and consulting projects for sectors such as life sciences, medical devices, and healthcare IT. His capabilities in qualitative and quantitative analysis have resulted in positive client outcomes. Working on niche market trends, opportunities, sales, and forecasted value is part of his skill set.

Get In Touch

Leave a Comment

FAQs

How much is the Companion Diagnostics Market?

USD 25,300.58 Million (2035)

What is the growth rate of the Companion Diagnostics Market?

12.68%

Which region held the largest market share in the Companion Diagnostics Market?

North America

Who are the key players in the Companion Diagnostics Market?

Qiagen, Bio-Techne, BioMérieux, Thermo Fisher Scientific Inc., Illumina, Inc., Agilent Technologies, Inc., F. Hoffmann-la Roche Ltd.

Which Indication had the largest market share in the Companion Diagnostics Market?

<em>C</em>ancer

Market Summary

According to Market Research Future analysis, the Companion Diagnostics Market size was valued at USD 6,828.25 million in 2024. The market is projected to grow from USD 7,694.07 million in 2025 to USD 25,300.58 million by 2035, exhibiting a CAGR of 12.68% during the forecast period 2025–2035. North America led the market with over 0.04% share, generating around USD 3 million in revenue.
 
Rising global cancer burden and expanding precision medicine adoption are driving companion diagnostics demand. Increasing biomarker-based treatment decisions, targeted therapy approvals, and personalized oncology approaches are accelerating adoption of companion diagnostics across clinical workflows and drug development pipelines worldwide.
 

  • According to the World Health Organization (WHO), nearly 20 million new cancer cases and 9.7 million deaths occurred globally in 2022, while 1 in 5 individuals develop cancer during their lifetime, significantly increasing demand for biomarker-based testing and companion diagnostics supporting personalized treatment decisions.

Key Market Trends & Highlights

The Companion Diagnostics Market is currently valued in the high single to low double digit billions of dollars and is expanding rapidly, underpinned by the rise of precision medicine, oncology targeted therapies, and biomarker driven drug development.

  • North America leads Companion Diagnostics Market, accounting for over 0.04% global revenue in 2024. PCR technology captured 36% market share, driven by high accuracy and cost-effective testing adoption. Assays, reagents & kits segment held 44% share, supported by growing biomarker testing demand. Cancer indication dominated market with 63% share in 2024, driven by increasing global cancer burden.

Market Size & Forecast

2024 Market Size 6,828.25 (USD Million)
2035 Market Size 25,300.58 (USD Million)
CAGR (2025 - 2035) 12.68%

Major Players

Companies such as Qiagen, <a href="https://www.bio-techne.com/services/custom-services">Bio-Techne</a>, BioMérieux, Thermo Fisher Scientific Inc., Illumina, Inc., <a href="https://www.agilent.com/en?Campaign_Source=PAN_PSM_Brand_G&amp;amp;gclsrc=aw.ds&amp;amp;gad_source=1&amp;amp;gad_campaignid=9969295656&amp;amp;gbraid=0AAAAADSHcWd4RL2oaYXnpO9cIBdZFikEg&amp;amp;gclid=CjwKCAjw-dfOBhAjEiwAq0RwI0j9rykg2fR_Vt8VdQaXrrlaG8fbjd2keTaphxMxA82VuCq71V8AXxoCAdgQAvD_BwE">Agilent Technologies</a>, Inc., F. Hoffmann-la Roche Ltd. are some of the major participants in the global market.

Market Trends

The global companion diagnostics (CDx) market sits at the center of the precision medicine ecosystem, evolving from niche oncology tools into a strategic pillar for targeted therapy development and clinical decision-making. Market dynamics are shaped by a strong push pull interaction between powerful growth drivers, structural restraints, and emerging technology and therapeutic-area opportunities.

On the demand side, rising cancer and chronic disease prevalence, together with the growing adoption of targeted therapies and precision medicine, is rapidly increasing the clinical need for biomarker-based tests that can identify “right patient right drug right dose” combinations. At the same time, rapid technological advances in NGS, PCR, automated and digital platforms, AI/ML analytics, and liquid biopsy are expanding the range, speed, and sensitivity of CDx solutions, while closer drug diagnostic co-development and increasing regulatory approvals are embedding CDx directly into therapeutic labels and clinical pathways.

Counterbalancing these growth forces are substantial restraints that continue to limit the scale and equity of deployment. CDx development and validation remain capital-intensive and high risk, especially for multi-gene NGS assays and niche indications, which narrows participation to well-capitalized players. Regulatory complexity and varied approval pathways across the U.S., Europe, Japan, and emerging markets add time, cost, and uncertainty, as sponsors must navigate different evidentiary standards and device classifications while aligning with drug approval timelines.

Even after approval, limited and fragmented reimbursement, uneven access to advanced testing infrastructure, and low awareness among payers, clinicians, and patients frequently create a gap between theoretical availability and real-world utilization, particularly outside major academic centers and in low- and middle-income countries. Despite these frictions, the opportunity landscape is broadening. Expansion beyond oncology into cardiovascular, metabolic, autoimmune, infectious, and rare diseases promises to multiply the addressable patient pool as robust biomarkers and targeted agents emerge in these areas.

Companion Diagnostic Market Market Drivers

Rising Cancer & Chronic Disease Prevalence

The rising prevalence of cancer and chronic diseases significantly drives the Companion Diagnostics Market by heightening demand for precision medicine tools that identify patients suitable for targeted therapies, optimizing treatment outcomes and minimizing ineffective interventions. In 2022, approximately 20 million new cancer cases occurred worldwide, with projections estimating 35.3 million by 2050 a 76.6% increase particularly sharp in low human development index (HDI) countries at 142%, underscoring the urgent need for biomarker-driven diagnostics. 

 
Chronic conditions exacerbate this, as nearly three-quarters of the global population is expected to live with at least one by 2025, including 76.4% of U.S. adults in 2023 facing issues like hypertension (34.5%), high cholesterol (35.3%), and diabetes (12.1%), which fuel demands for tests in oncology, cardiovascular, and neurological disorders. For instance, HER2 testing in breast cancer, affecting millions annually, pairs with trastuzumab to boost survival rates, while PD-L1 assays like 22C3 guide pembrolizumab use in non-small cell lung cancer, matching therapies to tumor profiles for up to 30-40% response improvements in eligible patients.

Increasing Drug–Diagnostic Co-Development & Regulatory Approvals

Increasing drug-diagnostic co-development and regulatory approvals propel the Companion Diagnostics Market by synchronizing biomarker tests with targeted therapies, ensuring timely patient access to precision treatments through streamlined parallel pathways. By 2025, co-development has become essential for oncology, immunology, and rare diseases, with structured workflows from biomarker identification to integrated clinical trials aligning timelines for pivotal approvals.
 
The FDA lists over 44 approved companion diagnostics by 2020, surging to more than 35 additional approvals between 2011 and recent years, predominantly for hematological and oncological drugs via platforms like IHC, NGS, and PCR, with most requiring Premarket Approval (PMA) as high-risk devices. For example, in Q1 2025, the FDA approved the Thera screen KRAS RGQ PCR Kit (QIAGEN) as a companion diagnostic for colorectal cancer patients with KRAS G12C mutations eligible for sotorasib, enabling precise stratification amid two such approvals that quarter.

Market Segment Insights

By Test Type: EGFR Mutation Testing (largest market) vs PD-1 Testing (fastest growing)

Based on test type, the Companion Diagnostics Market has been segmented into HER2 Testing, PD-1 Testing, EGFR Mutation Testing, ALK Rearrangement Testing, and Others. EGFR mutation testing holds the largest share, accounting for 31% of the market, primarily due to its extensive use in NSCLC, which represents a significant portion of global lung cancer cases. With lung cancer being one of the leading causes of cancer-related deaths worldwide, the demand for accurate diagnostic tools has surged. 

EGFR testing helps identify patients eligible for targeted therapies like tyrosine kinase inhibitors (TKIs), improving survival rates and treatment outcomes. The growing incidence of NSCLC and other EGFR-related cancers is a key driver for market expansion. PD-1 testing is essential for identifying patients who will benefit from immune checkpoint inhibitors such as pembrolizumab and nivolumab. With immunotherapy becoming a standard treatment for cancers like non-small cell lung cancer (NSCLC), melanoma, and renal cell carcinoma, the demand for PD-1 biomarker testing has surged. This trend is fuelled by the growing clinical evidence supporting PD-1 inhibitors’ effectiveness, making PD-1 testing a critical step in precision oncology.

By Product & Services: assays, reagents & kits (largest market) vs instruments/systems (fastest-growing)

Based on Product &amp; Services, the Companion Diagnostics Market has been segmented into assays, reagents &amp; kits, instruments/systems, and software &amp; services, with assays holding the largest share of 44% of the market. Assays, reagents, and kits are essential components for performing biomarker-based tests like HER2, EGFR, ALK, and PD-1. The growing need for precision in cancer diagnostics and personalized medicine has increased demand for high-quality reagents and kits that ensure accurate results. 

Their critical role in maintaining test reliability makes them indispensable in clinical workflows, driving consistent market growth. Healthcare providers are increasingly adopting automated instruments to improve efficiency and reduce human error in biomarker testing. These systems enable high-throughput analysis, faster turnaround times, and standardized results, which are critical for precision medicine. Automation also supports scalability in large hospitals and diagnostic labs, driving strong demand for advanced instruments.

By Technology: polymerase chain reaction (PCR) (largest market) vs next-generation sequencing (NGS) (fastest-Growing)

Based on technology, the Companion Diagnostics Market has been segmented into polymerase chain reaction (PCR), next-generation sequencing (NGS), immunohistochemistry (IHC), fluorescence in-situ hybridization (FISH), and others, with PCR holding the largest share of 36% of the market. PCR technology offers exceptional sensitivity and specificity for detecting genetic mutations and biomarkers, making it a preferred choice for companion diagnostics. Its ability to amplify small amounts of DNA ensures accurate results even from limited samples, which is critical for early cancer detection and personalized treatment planning. 

This reliability drives widespread adoption in clinical settings. Further, cost-effectiveness of PCR compared to advanced technologies like NGS and widely availability and affordability make it suitable for routine testing in hospitals and diagnostic labs, especially in emerging markets. The combination of low cost and high accuracy positions PCR as a dominant technology in companion diagnostics. NGS enables simultaneous analysis of multiple genes and biomarkers in a single test, providing a complete genomic profile of the patient. This capability is crucial for identifying complex mutations and guiding personalized cancer therapies. Its ability to detect rare variants and resistance mutations makes NGS indispensable in precision oncology, driving strong adoption.

By Indication: cancer (largest market) vs infectious diseases (fastest-Growing)

Based on indication, the Companion Diagnostics Market has been segmented into cancer, neurological disorders, cardiovascular disorders, and infectious diseases, with cancer accounting for 63% of the market share. Cancer remains one of the leading causes of mortality worldwide, with millions of new cases diagnosed annually. The growing prevalence of cancers such as breast, lung, colorectal, and gastric significantly increases the need for accurate biomarker testing. 

For instance, as per the report published by the World Health Organization in 2024, it has been reported that, in 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths. The increasing prevalence of infectious diseases such as HIV, hepatitis, tuberculosis, and emerging viral infections drives demand for accurate diagnostic tools. Companion diagnostics help identify patients who will respond to specific antiviral or antimicrobial therapies, improving treatment outcomes and reducing resistance. This growing disease burden is a major driver for market expansion.

By End User: Biopharmaceutical and Biotechnology Companies (largest market) vs CROs and CDMOs (fastest-Growing)

Based on end users, the Companion Diagnostics Market has been segmented into Biopharmaceutical and Biotechnology Companies, CROs and CDMOs, and Others, with Biopharmaceutical and Biotechnology Companies holding the largest share at 41% of the market. Biopharmaceutical and biotech companies increasingly rely on companion diagnostics to identify patient populations for targeted therapies. This integration improves clinical trial success rates, reduces costs, and accelerates regulatory approvals. 

By ensuring that drugs are tested on genetically suitable patients, these companies enhance treatment efficacy and safety, driving demand for companion diagnostic solutions. CROs and CDMOs help pharmaceutical companies meet stringent regulatory requirements for companion diagnostics and drug approvals. Their ability to manage complex documentation, quality control, and global compliance drives demand for outsourcing these functions, fuelling growth in this segment. Developing and manufacturing companion diagnostics in-house can be expensive and resource-intensive. CROs and CDMOs offer cost-effective solutions with scalable infrastructure, allowing pharma companies to focus on core R&amp;D while leveraging external expertise for diagnostics development and production.

Get more detailed insights about Companion Diagnostics Market Research Report - Forecast Till 2035

Regional Insights

North America: Expanding cancer survivors

North America leads in the Companion Diagnostics Market Size, accounting for over 0.04% of the global revenue in 2024, the U.S. it is estimated that over 2 million new cancer cases and more than 618,000 deaths, with a growing population of 18.6 million cancer survivors projected to reach 22.4 million by 2035. This epidemiological surge drives demand for personalized medicine, in which CDx play a central role in matching patients with specific targeted therapies effectively expanding the CDx market. Moreover, the enhanced FDA regulatory framework contributes significantly to market growth.

Since 2014, the FDA has issued multiple clear regulatory guidelines (e.g., “In Vitro Companion Diagnostic Devices”) to support early and effective co-development of therapeutics and companion diagnostics. In 2023–2024 alone, the FDA authorized 11 new companion diagnostic claims and expanded nine existing ones associated with oncology IVD devices. This enhanced clarity enables smoother regulatory pathways and faster time-to-market for CDx products, significantly stimulating innovation and investment in the sector.

Companion Diagnostics Market Regional Insights

Europe: Expanding clinical evidence

In Europe, the growth of the companion diagnostics (CDx) market in Europe is being driven by a confluence of regulatory advancements, expanding clinical evidence, public health imperatives, and rising disease burdens—all underpinned by authoritative data from EU institutions and the WHO. The introduction and implementation of the In Vitro Diagnostic Regulation (IVDR, EU 2017/746), which became fully applicable in May 2022, represent a significant turning point.

This regulation imposes stricter performance evaluation, clinical evidence, and transparency requirements for high-risk IVDs, including CDx. Under IVDR, notified bodies must now engage in formal consultations with the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) on companion diagnostics, and the EMA has established a dedicated CHMP CDx Expert Group to support these reviews, helping accelerate regulatory alignment between diagnostics and therapies.

Asia Pacific: Rapidly clinical evidence

Asia Pacific, the growth of the Companion Diagnostics (CDx) market in the Asia Pacific region is propelled by a convergence of rapidly rising cancer incidence, maturing regulatory frameworks, expanding government screening programs, and increasing reimbursement support. According to GLOBOCAN 2022, Asia recorded nearly 9.83 million new cancer cases and 5.46 million deaths, accounting for roughly 50% of global cancer incidence and 58% of cancer deaths.

Within individual markets, the burden is stark: China reported approximately 4.82 million cases in 2022, India logged 1.41 million cases with almost 917,000 deaths, and Japan saw over 1 million cases that year—all underscoring an urgent demand for precision medicine tools like CDx that enable targeted therapy and improved outcomeslutide.

Key Players and Competitive Insights

Many global, regional, and local vendors characterize the Companion Diagnostics Market. The market is highly competitive, with all the players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth.
 
The vendors compete based on cost, product quality, reliability, and government regulations. Vendors must provide cost-efficient, high-quality products to survive and succeed in an intensely competitive market.The major players in the market Include Qiagen, Bio-Techne, BioMérieux, Thermo Fisher Scientific Inc., Illumina, Inc., Agilent Technologies, Inc., F. Hoffmann-la Roche Ltd, strategic market developments and decisions to improve operational effectiveness.

Key Companies in the Companion Diagnostic Market include

Industry Developments

June 2025: Alma's strategic focus lies in delivering smart, user-friendly systems that combine clinical efficacy with operational efficiency. The company continues to expand its global reach through innovation-led R&D, regulatory compliance, and practitioner education. Alma’s products hold certifications from leading regulatory bodies, including the U.S. FDA, CE Mark, TGA, Health Canada, and other regional authorities. In line with its digital transformation goals, Alma incorporates smart interfaces, data-driven treatment protocols, and IoT-ready infrastructure into selected platforms to enhance treatment consistency, safety, and practice efficiency.

June 2025: Bausch + Lomb's primary objective is to expand the proportion of externally generated ideas in its pipeline strategy, with a focus on internal research and strategic alliances with the outside world. Its focus on R&D expenditure is also on growing its product portfolio. By acquiring small companies and collaborating with bigger companies, it also seeks to increase its global market share. Its main line of business is the production of pharmaceuticals and eye care products. In addition, the company seeks to remain a leader in technology and continue offering unique, superior products through an international distribution network.

September 2025: Venus Concept places strategic emphasis on continuous innovation, technology integration, and practitioner-focused support. The company channels significant investment into research and development to engineer next-generation, non-invasive and minimally invasive solutions that address high-demand treatment areas such as body contouring, cellulite reduction, skin tightening, and hair restoration. Its proprietary platforms—integrating technologies like diode laser lipolysis, multi-polar radiofrequency, pulsed electromagnetic fields, and EMS—are designed to deliver clinically validated outcomes with enhanced patient comfort and minimal downtime.

Future Outlook

Companion Diagnostic Market Future Outlook

The Companion Diagnostics Market size is projected to reach USD 25,300.58 million by 2035, growing at a CAGR of 12.68%, driven by increasing demand for high-performance computing and enhanced security features.

New opportunities lie in:

  • <p>Expansion beyond oncology into other therapeutic areas</p>
  • <p>Growth in bioinformatics, software &amp; services supporting CDx.</p>

By 2035, the Companion Diagnostic Market is expected to be robust, reflecting substantial growth and innovation.

Market Segmentation

Companion Diagnostics Market by End User Outlook

  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others

Companion Diagnostics Market by Test Type Outlook

  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others

Companion Diagnostics Market by Indication Outlook

  • cancer
  • neurological disorders
  • cardiovascular disorders
  • infectious diseases

Companion Diagnostics Market by Technology Outlook

  • polymerase chain reaction (PCR)
  • next-generation sequencing (NGS)
  • immunohistochemistry (IHC)
  • Fluorescence In-Situ Hybridization (FISH)
  • others

Companion Diagnostics Market by Product & Services Outlook

  • assays
  • reagents & kits
  • instruments/systems
  • software & services

Report Scope

Market Size 2024

6,828.25 (USD Million)

Market Size 2025

7694.07 (USD Million)

Market Size 2035

25,300.58 (USD Million)

Compound Annual Growth Rate (CAGR)

12.68% (2025 - 2035)

Report Coverage

Revenue Forecast, Competitive Landscape, Growth Factors, and Trends

Base Year

2024

Market Forecast Period

2025 - 2035

Historical Data

2019 - 2023

Market Forecast Units

USD Million

Key Companies Profiled

Qiagen, Bio-Techne, BioMérieux, Thermo Fisher Scientific Inc., Illumina, Inc., Agilent Technologies, Inc., F. Hoffmann-la Roche Ltd.

Segments Covered

By Test Type, By Product & Services, By Technology, By Indication, By End User

Key Market Opportunities

Expansion beyond oncology into other therapeutic areas.

Growth in bioinformatics, software & services supporting CDx.

Key Market Dynamics

High Cost & Capital Investment for CDx Development and Testing.

Regulatory Complexity and Varied Approval Pathways.

Limited Reimbursement, Uneven Access & Awareness.

Region Covered

North America, Europe, Asia Pacific.

 

FAQs

How much is the Companion Diagnostics Market?

USD 25,300.58 Million (2035)

What is the growth rate of the Companion Diagnostics Market?

12.68%

Which region held the largest market share in the Companion Diagnostics Market?

North America

Who are the key players in the Companion Diagnostics Market?

Qiagen, Bio-Techne, BioMérieux, Thermo Fisher Scientific Inc., Illumina, Inc., Agilent Technologies, Inc., F. Hoffmann-la Roche Ltd.

Which Indication had the largest market share in the Companion Diagnostics Market?

<em>C</em>ancer

  1. EXECUTIVE SUMMARY
  2. MARKET INTRODUCTION
    1. DEFINITION
    2. SCOPE OF THE STUDY
    3. RESEARCH OBJECTIVE
    4. MARKET STRUCTURE
  3. RESEARCH METHODOLOGY
    1. OVERVIEW
    2. DATA FLOW
      1. Data Mining Process
    3. PURCHASED DATABASE:
    4. SECONDARY SOURCES:
      1. Secondary Research data flow:
    5. PRIMARY RESEARCH:
      1. Primary Research Data Flow:
      2. Primary Research: Number of Interviews conducted
    6. APPROACHES FOR MARKET SIZE ESTIMATION:
      1. Revenue Analysis Approach
    7. DATA FORECASTING
      1. Data forecasting Type
    8. DATA MODELING
      1. microeconomic factor analysis:
      2. Data modeling:
    9. TEAMS AND ANALYST CONTRIBUTION
  4. MARKET DYNAMICS
    1. INTRODUCTION
    2. DRIVERS
      1. Rising Cancer & Chronic Disease Prevalence
      2. Growing Adoption of Targeted Therapies and Precision Medicine
      3. Technological Advances
      4. Increasing Drug–Diagnostic Co-Development & Regulatory Approvals
    3. RESTRAINTS
      1. High Cost & Capital Investment for CDx Development and Testing
      2. Regulatory Complexity and Varied Approval Pathways
      3. Limited Reimbursement, Uneven Access & Awareness
    4. OPPORTUNITIES
      1. Expansion beyond oncology into other therapeutic areas
      2. Growth in bioinformatics, software & services supporting CDx
  5. MARKET FACTOR ANALYSIS
    1. PORTER'S FIVE FORCES MODEL
      1. Threat of New Entrants
      2. BARGAINING POWER OF SUPPLIERS
      3. Threat of Substitutes
      4. Bargaining Power of Buyers
      5. Intensity of Rivalry
    2. IMPACT ANALYSIS OF COVID-19
      1. Disruption in Diagnostic Testing and Oncology Procedures
      2. Supply Chain Disruptions
      3. Changes in Patient Behavior and Clinical Workflows
      4. Impact on R&D and Innovation
    3. COMPANION DIAGNOSTIC ANALYSIS FOR KEYTRUDA, TECENTRIQ, AND LIBTAYO
    4. PDL1 SALES DATA GLOBALLY, 2019-2035 (USD MILLION)
    5. MARKET SHARE BY DRUG GLOBAL, REGIONAL AND COUNTRY LEVEL 2024 (%)
      1. GLOBAL MARKET SHARE BY DRUG, 2024 (%)
      2. North America MARKET SHARE BY DRUG, 2024 (%)
      3. Europe MARKET SHARE BY DRUG, 2024 (%)
      4. ASIA-PACIFIC MARKET SHARE BY DRUG, 2024 (%)
    6. MARKET SHARE BY CLONE GLOBAL, REGIONAL AND COUNTRY LEVEL 2024 (%)
      1. GLOBAL MARKET SHARE BY clone, 2024 (%)
      2. North America MARKET SHARE BY CLONE, 2024 (%)
      3. EUROPE MARKET SHARE BY CLONE, 2024 (%)
      4. ASIA-PACIFIC MARKET SHARE BY CLONE, 2024 (%)
    7. QUALITATIVE ANALYSIS OF PD-L1 TESTING CUT-OFFS
    8. PDL1 SALES DATA GLOBALLY, (2019-2035), BY APPLICATION
    9. PRICING ANALYSIS, 2024 (USD)
  6. GLOBAL COMPANION DIAGNOSTICS MARKET, BY TEST TYPE
    1. OVERVIEW
    2. HER2 TESTING
    3. PD-1 TESTING
    4. EGFR MUTATION TESTING
    5. ALK REARRANGEMENT TESTING
    6. OTHERS
  7. GLOBAL COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES
    1. OVERVIEW
    2. ASSAYS, REAGENTS & KITS
    3. INSTRUMENTS/SYSTEMS
    4. SOFTWARE & SERVICES
  8. GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY
    1. OVERVIEW
    2. POLYMERASE CHAIN REACTION (PCR)
    3. NEXT-GENERATION SEQUENCING (NGS)
    4. IMMUNOHISTOCHEMISTRY (IHC)
    5. FLUORESCENCE IN-SITU HYBRIDIZATION (FISH)
    6. OTHERS
  9. GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION
    1. OVERVIEW
    2. CANCER
    3. NEUROLOGICAL DISORDERS
    4. CARDIOVASCULAR DISORDERS
    5. INFECTIOUS DISEASES
  10. GLOBAL COMPANION DIAGNOSTICS MARKET, BY END USER
    1. OVERVIEW
    2. BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
    3. CROS AND CDMOS
    4. OTHERS
  11. GLOBAL COMPANION DIAGNOSTICS MARKET, BY REGION
    1. OVERVIEW
    2. NORTH AMERICA
      1. US
      2. CANADA
    3. EUROPE
      1. GERMANY
      2. france
      3. UK
      4. ITALY
      5. Spain
      6. Denmark
      7. Finland
      8. Iceland
      9. Norway
      10. Sweden
      11. Rest of Europe
    4. ASIA-PACIFIC
      1. India
      2. Japan
      3. South Korea
      4. Australia
      5. Rest of Asia-Pacific
  12. COMPETITIVE LANDSCAPE
    1. INTRODUCTION
    2. MARKET SHARE ANALYSIS, 2024
    3. COMPETITOR DASHBOARD
    4. PUBLIC PLAYERS STOCK SUMMARY
    5. COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL
    6. KEY DEVELOPMENTS & GROWTH STRATEGIES
      1. Product/service launch
      2. acquisition
      3. Accreditation
      4. Collaboration/ Partnership
  13. COMPANY PROFILES
    1. QIAGEN
      1. COMPANY OVERVIEW
      2. FINANCIAL OVERVIEW
      3. products OFFERed
      4. KEY DEVELOPMENTS
      5. SWOT ANALYSIS
      6. KEY STRATEGIES
      7. products OFFERed
      8. SWOT ANALYSIS
    2. BIOMÉRIEUX
      1. COMPANY OVERVIEW
      2. FINANCIAL OVERVIEW
      3. products OFFERed
      4. KEY DEVELOPMENTS
      5. SWOT ANALYSIS
      6. KEY STRATEGIES
    3. LEICA BIOSYSTEMS NUSSLOCH GMBH
      1. COMPANY OVERVIEw
      2. FINANCIAL OVERVIEW
      3. products OFFERed
      4. KEY DEVELOPMENTS
      5. KEY STRATEGIES
    4. NG BIOTECH
      1. COMPANY OVERVIEW
      2. FINANCIAL OVERVIEW
      3. products OFFERed
      4. KEY STRATEGIES
    5. THERMO FISHER SCIENTIFIC INC.
      1. COMPANY OVERVIEW
      2. FINANCIAL OVERVIEW
      3. products OFFERed
      4. KEY DEVELOPMENTs
      5. SWOT ANALYSIS
      6. Key Strategy
    6. ILLUMINA, INC.
      1. COMPANY OVERVIEW
      2. FINANCIAL OVERVIEW
      3. PRODUCTS OFFERed
      4. KEY DEVELOPMENTS
      5. KEY STRATEGIES
    7. AGILENT TECHNOLOGIES, INC.
      1. COMPANY OVERVIEW
      2. FINANCIAL OVERVIEW
      3. PRODUCTS OFFERED
      4. KEY DEVELOPMENTS
      5. SWOT ANALYSIS
      6. KEY STRATEGIES
    8. FOUNDATION MEDICINE INC. (F. HOFFMANN-LA ROCHE LTD )
      1. COMPANY OVERVIEW
      2. FINANCIAL OVERVIEW
      3. productS OFFERED
      4. KEY DEVELOPMENTs
      5. KEY STRATEGIES
    9. MYRIAD GENETICS, INC.
      1. COMPANY OVERVIEW
      2. FINANCIAL OVERVIEW
      3. productS OFFERED
      4. KEY DEVELOPMENTs
      5. KEY STRATEGIES
  14. DATA CITATIONS
    1.  
  15. LIST OF TABLES
  16. QFD MODELING FOR MARKET SHARE ASSESSMENT
  17. COMPANION DIAGNOSTIC ANALYSIS FOR KEYTRUDA, TECENTRIQ, AND LIBTAYO
  18. PDL1 SALES DATA GLOBALLY, 2019-2035 (USD MILLION)
  19. PD-L1 TESTING CUT-OFFS
  20. PDL1 SALES DATA GLOBALLY, (2019-2035), BY APPLICATION
  21. PRICING ANALYSIS, 2024 (USD)
  22. GLOBAL COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2024 & 2035 (USD MILLION)
  23. GLOBAL COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2024 & 2035 (TEST VOLUME)
  24. GLOBAL COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TEST TYPE, 2024 & 2035 (USD MILLION)
  25. GLOBAL COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TEST TYPE, 2024 & 2035 (TEST VOLUME)
  26. GLOBAL COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICES, 2024 & 2035 (USD MILLION)
  27. GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 & 2035 (USD MILLION)
  28. GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024 & 2035 (USD MILLION)
  29. GLOBAL COMPANION DIAGNOSTICS MARKET, BY END USER, 2024 & 2035 (USD MILLION)
  30. GLOBAL COMPANION DIAGNOSTICS MARKET, BY REGION, 2019-2035 (USD MILLION)
  31. GLOBAL COMPANION DIAGNOSTICS MARKET, BY REGION, 2019-2035 (TEST VOLUME)
  32. NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
  33. NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION)
  34. NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME)
  35. NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-2035 (USD MILLION)
  36. NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-2035 (TEST VOLUME)
  37. NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICES, 2019-2035 (USD MILLION)
  38. NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2035 (USD MILLION)
  39. NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-2035 (USD MILLION)
  40. NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-2035 (USD MILLION)
  41. US: COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION)
  42. US: COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME)
  43. US: COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-2035 (USD MILLION)
  44. US: COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-2035 (TEST VOLUME)
  45. US: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICES, 2019-2035 (USD MILLION)
  46. US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2035 (USD MILLION)
  47. US: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-2035 (USD MILLION)
  48. US: COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-2035 (USD MILLION)
  49. CANADA: COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION)
  50. CANADA: COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME)
  51. CANADA: COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-2035 (USD MILLION)
  52. CANADA: COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-2035 (TEST VOLUME)
  53. CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICES, 2019-2035 (USD MILLION)
  54. CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2035 (USD MILLION)
  55. CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-2035 (USD MILLION)
  56. CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-2035 (USD MILLION)
  57. EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
  58. EUROPE COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2019-H-2035 (TEST VOLUME)
  59. EUROPE COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION)
  60. EUROPE COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME)
  61. EUROPE COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION)
  62. EUROPE COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  63. EUROPE COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  64. EUROPE COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  65. EUROPE COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  66. EUROPE COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  67. GERMANY COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION)
  68. GERMANY COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME)
  69. GERMANY COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION)
  70. GERMANY COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  71. GERMANY COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  72. GERMANY COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  73. GERMANY COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  74. GERMANY COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  75. FRANCE COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION)
  76. FRANCE COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME)
  77. FRANCE COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION)
  78. FRANCE COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  79. FRANCE COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  80. FRANCE COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  81. FRANCE COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  82. FRANCE COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  83. UK COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION)
  84. UK COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME)
  85. UK COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION)
  86. UK COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  87. UK COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  88. UK COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  89. UK COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  90. UK COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  91. ITALY COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION)
  92. ITALY COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME)
  93. ITALY COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION)
  94. ITALY COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  95. ITALY COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  96. ITALY COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  97. ITALY COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  98. ITALY COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  99. SPAIN COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION)
  100. SPAIN COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME)
  101. SPAIN COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION)
  102. SPAIN COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  103. SPAIN COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  104. SPAIN COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  105. SPAIN COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  106. SPAIN COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  107. DENMARK COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION)
  108. DENMARK COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME)
  109. DENMARK COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION)
  110. DENMARK COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  111. DENMARK COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  112. DENMARK COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  113. DENMARK COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  114. DENMARK COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  115. FINLAND COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION)
  116. FINLAND COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME)
  117. FINLAND COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION)
  118. FINLAND COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  119. FINLAND COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  120. FINLAND COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  121. FINLAND COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  122. FINLAND COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  123. ICELAND COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION)
  124. ICELAND COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME)
  125. ICELAND COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION)
  126. ICELAND COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  127. ICELAND COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  128. ICELAND COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  129. ICELAND COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  130. ICELAND COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  131. NORWAY COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION)
  132. NORWAY COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME)
  133. NORWAY COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION)
  134. NORWAY COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  135. NORWAY COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  136. NORWAY COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  137. NORWAY COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  138. NORWAY COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  139. SWEDEN COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION)
  140. SWEDEN COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME)
  141. SWEDEN COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION)
  142. SWEDEN COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  143. SWEDEN COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  144. SWEDEN COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  145. SWEDEN COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  146. SWEDEN COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  147. REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (USD MILLION)
  148. REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-H-2035 (TEST VOLUME)
  149. REST OF EUROPE COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION)
  150. REST OF EUROPE COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  151. REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  152. REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  153. REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  154. REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  155. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
  156. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2019-2035 (TEST VOLUME)
  157. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION)
  158. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME)
  159. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING , BY TYPE, 2019-H-2035 (USD MILLION)
  160. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  161. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  162. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  163. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  164. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  165. INDIA COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION)
  166. INDIA COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME)
  167. INDIA COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING , BY TYPE, 2019-H-2035 (USD MILLION)
  168. INDIA COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  169. INDIA COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  170. INDIA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  171. INDIA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  172. INDIA COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  173. JAPAN COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION)
  174. JAPAN COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME)
  175. JAPAN COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING , BY TYPE, 2019-H-2035 (USD MILLION)
  176. JAPAN COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  177. JAPAN COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  178. JAPAN COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  179. JAPAN COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  180. JAPAN COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  181. SOUTH KOREA COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION)
  182. SOUTH KOREA COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME)
  183. SOUTH KOREA COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING , BY TYPE, 2019-H-2035 (USD MILLION)
  184. SOUTH KOREA COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  185. SOUTH KOREA COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  186. SOUTH KOREA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  187. SOUTH KOREA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  188. SOUTH KOREA COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  189. AUSTRALIA COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION)
  190. AUSTRALIA COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME)
  191. AUSTRALIA COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (USD MILLION)
  192. AUSTRALIA COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  193. AUSTRALIA COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  194. AUSTRALIA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  195. AUSTRALIA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  196. AUSTRALIA COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  197. REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (USD MILLION)
  198. REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2035 (TEST VOLUME)
  199. REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING , BY TYPE, 2019-H-2035 (USD MILLION)
  200. REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, FOR PD-1 TESTING, BY TYPE, 2019-H-2035 (TEST VOLUME)
  201. REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BYPRODUCT & SERVICES, 2019-H-2035 (USD MILLION)
  202. REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-H-2035 (USD MILLION)
  203. REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019-H-2035 (USD MILLION)
  204. REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY END USER, 2019-H-2035 (USD MILLION)
  205. PRODUCT/SERVICE LAUNCH
  206. ACQUISITION/EXPANSION
  207. ACCREDITATION
  208. COLLABORATION/ PARTNERSHIP
  209. QIAGEN: PRODUCTS AND SERVICES OFFERED
  210. QIAGEN: KEY DEVELOPMENTS
  211. BIO-TECHNE: PRODUCTS AND SERVICES OFFERED
  212. BIOMÉRIEUX: PRODUCTS AND SERVICES OFFERED
  213. BIOMÉRIEUX: PRODUCTS OFFERED
  214. LEICA BIOSYSTEMS NUSSLOCH GMBH: PRODUCTS OFFERED
  215. LEICA BIOSYSTEMS NUSSLOCH GMBH: PRODUCTS OFFERED
  216. NG BIOTECH: PRODUCTS OFFERED
  217. THERMO FISHER SCIENTIFIC INC.: PRODUCTS AND SERVICES OFFERED
  218. THERMO FISHER SCIENTIFIC INC.: KEY DEVELOPMENTS
  219. ILLUMINA, INC.: PRODUCTS AND SERVICES OFFERED
  220. ILLUMINA, INC.: KEY DEVELOPMENTS
  221. AGILENT TECHNOLOGIES, INC.: PRODUCTS AND SERVICES OFFERED
  222. AGILENT TECHNOLOGIES, INC.: KEY DEVELOPMENTS
  223. FOUNDATION MEDICINE INC. (F. HOFFMANN-LA ROCHE LTD ): PRODUCTS AND SERVICES OFFERED
  224. MYRIAD GENETICS, INC.: PRODUCTS AND SERVICES OFFERED
  225. MYRIAD GENETICS, INC.: KEY DEVELOPMENTS
  226. LIST OF FIGURES
  227. GLOBAL COMPANION DIAGNOSTICS MARKET: STRUCTURE
  228. GLOBAL COMPANION DIAGNOSTICS MARKET: MARKET GROWTH AFFECTING FACTOR ANALYSIS (2019-2035)
  229. GLOBAL COMPANION DIAGNOSTICS MARKET DRIVER: IMPACT ANALYSIS
  230. GLOBAL COMPANION DIAGNOSTICS MARKET RESTRAINT: IMPACT ANALYSIS
  231. PORTER'S FIVE FORCES ANALYSIS: GLOBAL COMPANION DIAGNOSTICS MARKET
  232. GLOBAL MARKET SHARE ANALYSIS: BY DRUG, 2024
  233. NORTH AMERICA MARKET SHARE ANALYSIS: BY DRUG, 2024
  234. US MARKET SHARE ANALYSIS: BY DRUG, 2024
  235. EUROPE MARKET SHARE ANALYSIS: BY DRUG, 2024
  236. GERMANY MARKET SHARE ANALYSIS: BY DRUG, 2024
  237. UK MARKET SHARE ANALYSIS: BY DRUG, 2024
  238. ASIA-PACIFIC MARKET SHARE ANALYSIS: BY DRUG, 2024
  239. CHINA MARKET SHARE ANALYSIS: BY DRUG, 2024
  240. INDIA MARKET SHARE ANALYSIS: BY DRUG, 2024
  241. JAPAN MARKET SHARE ANALYSIS: BY DRUG, 2024
  242. GLOBAL MARKET SHARE ANALYSIS: BY CLONE, 2024
  243. NORTH AMERICA MARKET SHARE ANALYSIS: BY CLONE, 2024
  244. US MARKET SHARE ANALYSIS: BY CLONE, 2024
  245. EUROPE MARKET SHARE ANALYSIS: BY CLONE, 2024
  246. GERMANY MARKET SHARE ANALYSIS: BY CLONE, 2024
  247. UK MARKET SHARE ANALYSIS: BY CLONE, 2024
  248. ASIA-PACIFIC MARKET SHARE ANALYSIS: BY CLONE, 2024
  249. INDIA MARKET SHARE ANALYSIS: BY CLONE, 2024
  250. JAPAN MARKET SHARE ANALYSIS: BY CLONE, 2024
  251. GLOBAL COMPANION DIAGNOSTICS MARKET, TEST TYPE SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD MILLION)
  252. GLOBAL COMPANION DIAGNOSTICS MARKET, BY TEST TYPE, 2024 & 2035 (USD MILLION)
  253. GLOBAL COMPANION DIAGNOSTICS MARKET SHARE (%), BY TEST TYPE, 2024
  254. GLOBAL COMPANION DIAGNOSTICS MARKET, PRODUCT & SERVICES SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD MILLION)
  255. GLOBAL COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICES, 2024 & 2035 (USD MILLION)
  256. GLOBAL COMPANION DIAGNOSTICS MARKET SHARE (%), BY PRODUCT & SERVICES, 2024
  257. GLOBAL COMPANION DIAGNOSTICS MARKET, TECHNOLOGY SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD MILLION)
  258. GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 & 2035 (USD MILLION)
  259. GLOBAL COMPANION DIAGNOSTICS MARKET SHARE (%), BY TECHNOLOGY, 2024
  260. GLOBAL COMPANION DIAGNOSTICS MARKET, INDICATION SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD MILLION)
  261. GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION 2024 & 2035 (USD MILLION)
  262. GLOBAL COMPANION DIAGNOSTICS MARKET SHARE (%), BY INDICATION, 2024
  263. GLOBAL COMPANION DIAGNOSTICS MARKET, END USER SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD MILLION)
  264. GLOBAL COMPANION DIAGNOSTICS MARKET, BY END USER 2024 & 2035 (USD MILLION)
  265. GLOBAL COMPANION DIAGNOSTICS MARKET SHARE (%), BY END USER, 2024
  266. GLOBAL COMPANION DIAGNOSTICS MARKET, BY REGION, 2024 & 2035 (USD MILLION)
  267. GLOBAL COMPANION DIAGNOSTICS MARKET SHARE (%), BY REGION, 2024
  268. NORTH AMERICA MARKET ANALYSIS: COMPANION DIAGNOSTICS MARKET, 2019-2035 (USD MILLION)
  269. NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2024 & 2035 (USD MILLION)
  270. NORTH AMERICA COMPANION DIAGNOSTICS MARKET SHARE (%), BY COUNTRY, 2024
  271. EUROPE MARKET ANALYSIS: COMPANION DIAGNOSTICS MARKET, 2019-2035 (USD MILLION)
  272. EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2024 & 2035 (USD MILLION)
  273. EUROPE: COMPANION DIAGNOSTICS MARKET SHARE (%), BY COUNTRY, 2024
  274. ASIA-PACIFIC MARKET ANALYSIS: COMPANION DIAGNOSTICS MARKET, 2019-2035 (USD MILLION)
  275. ASIA-PACIFIC MARKET ANALYSIS: COMPANION DIAGNOSTICS MARKET, 2019-2035 (USD MILLION)
  276. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SHARE (%), BY COUNTRY, 2024
  277. GLOBAL COMPANION DIAGNOSTICS MARKET PLAYERS: COMPETITIVE ANALYSIS, 2024
  278. COMPETITOR DASHBOARD: GLOBAL COMPANION DIAGNOSTICS MARKET
  279. QIAGEN: FINANCIAL OVERVIEW SNAPSHOT
  280. QIAGEN: SWOT ANALYSIS
  281. BIO-TECHNE: FINANCIAL OVERVIEW SNAPSHOT
  282. BIO-TECHNE: SWOT ANALYSIS
  283. BIOMÉRIEUX: FINANCIAL OVERVIEW SNAPSHOT
  284. BIOMÉRIEUX: SWOT ANALYSIS
  285. THERMO FISHER SCIENTIFIC INC.: FINANCIAL OVERVIEW SNAPSHOT
  286. THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS
  287. ILLUMINA, INC.: FINANCIAL OVERVIEW SNAPSHOT
  288. AGILENT TECHNOLOGIES, INC.: FINANCIAL OVERVIEW SNAPSHOT
    1. Source: Annual Report, Press Releases, And MRFR Analysis
  289. AGILENT TECHNOLOGIES, INC.: SWOT ANALYSIS
  290. F. HOFFMANN-LA ROCHE LTD (FOUNDATION MEDICINE INC.): FINANCIAL OVERVIEW SNAPSHOT
  291. MYRIAD GENETICS, INC.: FINANCIAL OVERVIEW SNAPSHOT

Companion Diagnostics Market Segmentation

  • Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others

Companion Diagnostics Market Regional Outlook (USD Million, 2019-2035)

  • North America Outlook (USD Million, 2019-2035)
  • North America Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • North America Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • North America Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • North America Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • North America Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others
    • US Outlook (USD Million, 2019-2035)
  • US Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • US Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • US Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • US Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • US Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others
    • Canada Outlook (USD Million, 2019-2035)
  • Canada Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • Canada Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • Canada Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • Canada Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • Canada Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others
  • Europe Outlook (USD Million, 2019-2035)
  • Europe Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • Europe Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • Europe Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • Europe Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • Europe Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others
    • Germany Outlook (USD Million, 2019-2035)
  • Germany Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • Germany Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • Germany Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • Germany Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • Germany Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others
    • UK Outlook (USD Million, 2019-2035)
  • UK Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • UK Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • UK Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • UK Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • UK Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others

 

  • France Outlook (USD Million, 2019-2035)
  • France Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • France Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • France Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • France Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • France Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others
    • Russia Outlook (USD Million, 2019-2035)
  • Russia Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • Russia Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • Russia Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • Russia Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • Russia Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others
    • Italy Outlook (USD Million, 2019-2035)
  • Italy Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • Italy Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • Italy Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • Italy Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • Italy Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others
    • Spain Outlook (USD Million, 2019-2035)
  • Spain Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • Spain Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • Spain Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • Spain Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • Spain Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others
    • Rest Of Europe Outlook (USD Million, 2019-2035)
  • Rest Of Europe Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • Rest Of Europe Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • Rest Of Europe Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • Rest Of Europe Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • Rest Of Europe Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others
  • Asia-Pacific Outlook (USD Million, 2019-2035)
  • Asia-Pacific Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • Asia-Pacific Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • Asia-Pacific Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • Asia-Pacific Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • Asia-Pacific Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others
    • China Outlook (USD Million, 2019-2035)
  • China Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • China Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • China Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • China Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • China Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others
    • India Outlook (USD Million, 2019-2035)
  • India Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • India Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • India Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • India Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • India Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others
    • Japan Outlook (USD Million, 2019-2035)
  • Japan Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • Japan Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • Japan Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • Japan Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • Japan Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others
    • South Korea Outlook (USD Million, 2019-2035)
  • Global Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • Global Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • Global Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • Global Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • Global Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others
    • Rest of Asia-Pacific Outlook (USD Million, 2019-2035)
  • Rest of Asia-Pacific Companion Diagnostics Market by Test Type Outlook (USD Million, 2019-2035)
  • HER2 Testing
  • PD-1 Testing
  • EGFR Mutation Testing
  • ALK Rearrangement Testing
  • Others
  • Rest of Asia-Pacific Companion Diagnostics Market by Product & Services Outlook (USD Million, 2019-2035)
  • Assays, Reagents & Kits
  • Instruments/Systems
  • Software & Services
  • Rest of Asia-Pacific Companion Diagnostics Market by Technology Outlook (USD Million, 2019-2035)
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Fluorescence In Situ Hybridization (FISH)
  • Others
  • Rest of Asia-Pacific Companion Diagnostics Market by Indication Outlook (USD Million, 2019-2035)
  • Cancer
  • Neurological Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • Rest of Asia-Pacific Companion Diagnostics Market by End User Outlook (USD Million, 2019-2035)
  • Biopharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓